

## NN1177 TFA

<b>Cat. No.:</b>	HY-P10032A	
<b>Molecular Formula:</b>	$C_{206}H_{323}N_{51}O_{66} \cdot xC_2HF_3O_2$	
<b>Sequence:</b>	His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Tyr-Leu-Glu-Ser-Lys-Arg-Ala-Arg-Glu-Phe-Val-Gln-Trp-Leu-Leu-{Lys(gGlu-gGlu-Ser-Glu-Ser-gGlu-gGlu-C18 diacid)}-Thr-NH <sub>2</sub>	His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Tyr-Leu-Glu-Ser-Lys-Arg-Ala-Arg-Glu-Phe-Val-Gln-Trp-Leu-Leu-{Lys(γGlu-γGlu-Ser-Glu-Ser-γGlu-γGlu-C18 diacid)}-Thr-NH <sub>2</sub> (TFA)
<b>Sequence Shortening:</b>	H-{Aib}-QGTFTSDLSKYLESKRAREFVQWLL-{Lys(γGlu-γGlu-Ser-Glu-Ser-γGlu-γGlu-C18 diacid)}-T-NH <sub>2</sub>	
<b>Target:</b>	GCGR; Cytochrome P450; GLP Receptor	
<b>Pathway:</b>	GPCR/G Protein; Metabolic Enzyme/Protease	
<b>Storage:</b>	Sealed storage, away from moisture and light	
	Powder	-80°C 2 years -20°C 1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)	

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 100 mg/mL (Need ultrasonic)
-----------------	--

### BIOLOGICAL ACTIVITY

<b>Description</b>	NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	CYP3A4
<b>In Vitro</b>	NN1177 (100 nM, 3 days) TFA reduces CYP3A4 mRNA expression (57.2-71.7%) and activity (18.5-51.5%) in freshly isolated human hepatocytes <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	NN1177 (3 or 5 nmol/kg, s.c.) TFA induces body weight loss, loss of fat mass, and improvement in glucose tolerance in diet-induced obese (DIO) mice <sup>[1]</sup> . NN1177 (0.75-4 nmol/kg, s.c., once daily, 8 weeks) TFA reduces liver fat and inflammatory and fibrosis relevant biomarkers in C57Bl/6 mice fed a fructose and high fat rich diet (NASH model) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Simonsen L, et al. Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls. PLoS One. 2022 Mar 4;17(3):e0264974.

[2]. Monfeuga T, et al. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon

---

agonism in NASH patients. Mol Metab. 2023 Dec 7;79:101850.

[3]. Säll C, et al. In vitro CYP450 enzyme down-regulation by GLP-1/glucagon co-agonist does not translate to observed drug-drug interactions in the clinic. Drug Metab Dispos. 2022 Jun 9:DMD-AR-2022-000865.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA